Streetwise Articles
Milestone Shares More than Double After Presenting Updated Clinical Plan for Heart Condition
Source: Streetwise Reports (7/23/20)
Shares of Milestone Pharmaceuticals traded 150% higher after the company reported regulatory guidance and updated its clinical development plan for etripamil nasal spray designed for self-administered use in PSVT treatment.
More >
Biopharma's Therapeutic Jumps to Phase 2 Testing for COVID-19 'to Shut Down the Cytokine Storm'
Source: Streetwise Reports (7/22/20)
A development update on Sorrento Therapeutics' three coronavirus-related products is provided in a Dawson James report.
More >
HCA Healthcare Shares Move Up on Q2 Earnings and Resumption of Non-Emergency Procedures
Source: Streetwise Reports (7/22/20)
Shares of HCA Healthcare traded more than 10% higher after the company reported Q2/20 financial results and advised it has seen a gradual rise in patient volumes in May and June for elective and non-emergency procedures.
More >
Owens & Minor Shares Trade 75% Higher on Preliminary Q2 Earnings and Raised FY Guidance
Source: Streetwise Reports (7/21/20)
Shares of Owens & Minor reached a new 52-week high after the company reported preliminary Q2/20 results and raised FY/20 earnings guidance.
More >
AI Tech Firm Provides COVID-19 Contact Tracing Solution Update
Source: Streetwise Reports (7/20/20)
Loop Insights continues to educate governments and venue operators around the world about its easily implemented platform.
More >
Innovative Telehealth Company to Acquire Firm with Mental Health Platform
Source: Streetwise Reports (7/18/20)
With this transaction, CloudMD Software & Services will become Canada's first telemedicine company with both primary care and mental health care components.
More >
Dynavax Shares Rise 20% on Partnership with Mount Sinai to Develop Universal Flu Vaccine
Source: Streetwise Reports (7/17/20)
Shares of Dynavax Technologies reached a new 52-week high after the company reported that it is collaborating with Mount Sinai to develop a universal influenza vaccine candidate with CpG 1018 adjuvant.
More >
Cheap Valuation and Fastest Revenue Growth in Telemedicine? Analyst Says Yes.
Source: Peter Epstein for Streetwise Reports (7/17/20)
In the time of Covid-19, Peter Epstein of Epstein Research breaks down the investment opportunity offered by CloudMD.
More >
Threat Detection Company's AI Division Partners with Healthcare Firm to Increase Cancer Testing Access
Source: Streetwise Reports (7/16/20)
Patriot One Technologies reported its Xtract AI division is working with Canexia Health to increase access to cancer testing as part of the Digital Technology Supercluster COVID-19 Program project.
More >
AC Immune Shares Rise 19% as Firm Advances Alzheimer's Vaccine in Phase 1b/2a Trial
Source: Streetwise Reports (7/16/20)
AC Immune SA shares set a new 52-week high after the Swiss biotech firm reported that interim data from its Phase 1b/2a phospho-Tau Alzheimer's Vaccine study reconfirms promising safety and Tau-specific immunogenicity observed in the prior clinical trial.
More >
Taiwan Liposome Shares Rise 60% on Inhalable Liposomal HCQ Potential Covid-19 Treatment Claims
Source: Streetwise Reports (7/15/20)
Shares of Taiwan Liposome Co. reached a new 52-week high after the company released a manuscript describing how its inhalable liposomal hydroxychloroquine may provide clinical benefit and offer a potential treatment for Covid-19.
More >
Virtual Healthcare Tech Firm's Contract in Puerto Rico Is Its Largest by 400%
Source: Streetwise Reports (7/15/20)
Reliq Health Technologies' agreement with digiiMED makes its platform available to more than 200,000 patients.
More >
Potential Covid-19 Treatment Is Ready for Prime Time
Source: Streetwise Reports (7/14/20)
Small-cap Algernon Pharmaceuticals is about to begin a multinational Phase 2b/3 trial for Ifenprodil, a repurposed drug with a known safety record.
More >
INmune Bio Shares Double after Reporting Positive Phase 1b Alzheimer's Trial Data
Source: Streetwise Reports (7/14/20)
Shares of INmune Bio reached a new 52-week high after the company reported interim data from its Phase 1b study of XPro1595 that demonstrated decreased neuroinflammation in Alzheimer's patients.
More >
Analyst: Integrated Model Positioned to Monetize on Telehealth Emergence
Source: Streetwise Reports (7/13/20)
Echelon Capital Markets initiates coverage and explains why it is bullish on CloudMD Software & Services.
More >
Biotech Partners to Develop, Offer Alzheimer's Disease Tests
Source: Streetwise Reports (7/13/20)
ProMIS Neurosciences and its collaborator make their relationship official with a joint venture agreement.
More >
BioNTech Shares Rise as FDA Grants It and Partner Pfizer Fast Track Status for Two Covid-19 Vaccine Candidates
Source: Streetwise Reports (7/13/20)
Shares of BioNTech SE traded 15% higher after the company reported that, together with its partner Pfizer, it has received FDA Fast Track designation for two separate mRNA-based vaccine candidates against SARS-CoV-2.
More >
Threat Detection Company Forms Partnership to Advance Covid-19 Pathogen Screening
Source: Streetwise Reports (7/12/20)
Patriot One Technologies reported it is collaborating with ecoMine Technologies to advance pathogen screening applications as part of Canada's Digital Technology Supercluster's Covid-19 program.
More >
Altimmune Shares Up 20% Upon Forming Partnership for Intranasal COVID-19 Vaccine
Source: Streetwise Reports (7/9/20)
Altimmune shares reached a new 52-week high after the company reported it is collaborating with DynPort Vaccine on U.S. government funding efforts for AdCOVID™, its COVID-19 vaccine candidate.
More >
Biotech with Phase 3 Rheumatoid Arthritis and Psoriasis Trials Raises Capital, Now 'Funded Through Catalysts'
Source: Streetwise Reports (7/8/20)
An update on Can-Fite BioPharma's multiple drug treatment trials is provided in a Dawson James report.
More >
Preclinical COVID-19 Vaccine Data 'Encouraging'
Source: Streetwise Reports (7/8/20)
Updates on Sorrento Therapeutics' two coronavirus-related products are provided in an H.C. Wainwright & Co. report.
More >
Biopharma Starts Enrollment Screening for Phase 2 Pulmonary Fibrosis, Cough Trial
Source: Streetwise Reports (7/8/20)
In the study, Algernon Pharmaceuticals will test an existing drug that is being repurposed for these indications.
More >
Analyst: G1 Minimizes the Carnage of Chemotherapy
Source: Streetwise Reports (7/1/20)
ROTH Capital Partners initiates coverage on U.S. oncology biopharma G1 Therapeutics that is now filing an NDA.
More >
'Undervalued' Biopharma Gets Breakthrough Status for Alzheimer's Agitation Drug
Source: Streetwise Reports (7/1/20)
Axsome Therapeutics' latest news and clinical outlook are discussed in an H.C. Wainwright & Co. report.
More >
Life Sciences Firm Submits IND Application to FDA for Phase 3 COVID-19 Study
Source: Streetwise Reports (7/1/20)
Revive Therapeutics submitted an Investigational New Drug Application to the FDA for a Phase 3 confirmatory study of Bucillamine for treatment in SARS-CoV-2.
More >